[ad_1]
China’s National Pharmaceutical Group (Sinofarm) will examine the results of the third phase of an overseas clinical trial, to decide whether a double dose of its coronavirus vaccine should be accompanied by another revaccination, an official with the Chinese government said on Sunday. company.
According to Reuters, regulators and vaccine manufacturers are examining this possibility due to concerns that new strains of coronavirus could weaken the protection created by the vaccine against the parent strains.
Based on the results of clinical trials, the antibodies produced by the Chinese vaccine last for about six months, said Zhang Yuntao, vice president of CNBG, a branch of Sinofarm.
“Preliminary results have so far shown that additional revaccination can increase the number of antibodies and, at the same time, improve the ability of the vaccine to defend against virus mutations.” If additional revaccination is necessary and when it should be received, if so, it will be demonstrated in the results of the future third phase of clinical trials, “Zhang told a news conference.
Antibodies produced by a double dose of Sinofarm vaccine have a “very good” neutralizing effect on British and South African strains of the virus, he added, citing the results of laboratory tests that used blood samples from clinical study participants. .
Resistance to the Brazilian and Zimbabwean strains is currently being tested.
Read more about kovid-19 and the consequences of the pandemic in the country and the world on the page. Coronavirus
